Your browser doesn't support javascript.
loading
Exploring Hollow Mesoporous Silica Nanoparticles as a Nanocarrier in the Delivery of Foot-And-Mouth Disease Virus-like Particle Vaccines.
Ru, Jiaxi; Chen, Yu; Tao, Siyi; Du, Shaobo; Liang, Chao; Teng, Zhidong; Gao, Yuan.
Afiliação
  • Ru J; Institute for Advanced Research, Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang 325035, P. R. China.
  • Chen Y; State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, P. R. China.
  • Tao S; Institute for Advanced Research, Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang 325035, P. R. China.
  • Du S; Institute for Advanced Research, Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang 325035, P. R. China.
  • Liang C; College of Life Science and Technology, Gansu Agricultural University, Lanzhou 730070, P. R. China.
  • Teng Z; Institute for Advanced Research, Cixi Biomedical Research Institute, Wenzhou Medical University, Zhejiang 325035, P. R. China.
  • Gao Y; State Key Laboratory for Animal Disease Control and Prevention, College of Veterinary Medicine, Lanzhou University, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, P. R. China.
ACS Appl Bio Mater ; 7(2): 1064-1072, 2024 02 19.
Article em En | MEDLINE | ID: mdl-38286026
ABSTRACT
Virus-like particle (VLP) vaccine is considered to be the most promising candidate alternative to the traditional inactivated vaccine for foot-and-mouth disease (FMD). To elicit a desired immune response, hollow mesoporous silica nanoparticles (HMSNs) have been synthesized and utilized as a nanocarrier for FMD VLP vaccine delivery. The as-prepared HMSNs displayed a relatively small particle size (∼260 nm), large cavity (∼150 nm), and thin wall (∼55 nm). The inherent structural superiorities make them ideal nanocarriers for the FMD VLP vaccine, which exhibited good biocompatibility, great protein-loading capacity, high antibody-response level, and protective efficiency, even comparable to commercial adjuvant ISA 206. All the results suggested that HMSNs may be a valid nanocarrier in VLP-based vaccines.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Vírus da Febre Aftosa / Nanopartículas / Febre Aftosa Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vacinas / Vírus da Febre Aftosa / Nanopartículas / Febre Aftosa Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article